|
|
|
| The effect of obesity on immunotherapy for cancer
|
| 1Fang Ruoxin,2Yan Ling,1Liao Zhengkai |
| 1Department of Radiation and Medical Oncology Hubei Key Laboratory of Tumor Biological Behaviors Hubei Cancer Clinical Study Center Wuhan 430071, Hubei China;
2Department of Cardiology Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China |
|
|
|
|
Abstract Immunotherapy brings hope to cancer patients but the clinical outcome of cancer immunotherapy monotherapy or
combined therapy is not ideal. Screening the dominant population is an important means to improve the clinical benefit of patients and
reduce clinical complications. With economic development the proportion of obese people in China and the world is increasing which
has become a public health problem. There is growing evidence that obesity may affect the efficacy of immunotherapy and it has
become an effective feature for screening immunotherapy -beneficial populations but the mechanism remains unclear. The obesity
paradox refers to the fact that obesity leads to immunosuppression and promotes tumor progression in preclinical studies via chronic
inflammation the creation of an immunosuppressive tumor microenvironment disturbance of adipokines secretion and reduction of
beneficial bacteria in the gut microbiota but the clinical studies show that obese people can benefit more from immunotherapy. In order
to provide research directions and theoretical basis to explore the real impact of obesity status on the efficacy of immunotherapy in the
future and to improve the efficacy of immunotherapy we reviewed the impact of obesity on the efficacy of immunotherapy from both
clinical and preclinical studies and proposed possible explanations for the obesity paradox .
|
|
Received: 03 January 2022
|
|
|
|
|
|
|
